keyword
https://read.qxmd.com/read/38634273/in-vitro-and-in-silico-investigation-of-fda-approved-drugs-to-be-repurposed-against-alzheimer-s-disease
#1
JOURNAL ARTICLE
Didem Akkaya, Gökçe Seyhan, Suat Sari, Burak Barut
Alzheimer's disease (AD), one of the main causes of dementia, is a neurodegenerative disorder. Cholinesterase inhibitors are used in the treatment of AD, but prolonged use of these drugs can lead to serious side effects. Drug repurposing is an approach that aims to reveal the effectiveness of drugs in different diseases beyond their clinical uses. In this work, we investigated in vitro and in silico inhibitory effects of 11 different drugs on cholinesterases. The results showed that trimebutine, theophylline, and levamisole had the highest acetylcholinesterase inhibitory actions among the tested drugs, and these drugs inhibited by 68...
May 2024: Drug Development Research
https://read.qxmd.com/read/38633982/selection-of-lansoprazole-from-an-fda-approved-drug-library-to-inhibit-the-alzheimer-s-disease-seed-dependent-formation-of-tau-aggregates
#2
JOURNAL ARTICLE
Ahmed Imtiaz, Shotaro Shimonaka, Mohammad Nasir Uddin, Montasir Elahi, Koichi Ishiguro, Masato Hasegawa, Nobutaka Hattori, Yumiko Motoi
The efficacy of current treatments is still insufficient for Alzheimer's disease (AD), the most common cause of Dementia. Out of the two pathological hallmarks of AD amyloid-β plaques and neurofibrillary tangles, comprising of tau protein, tau pathology strongly correlates with the symptoms of AD. Previously, screening for inhibitors of tau aggregation that target recombinant tau aggregates have been attempted. Since a recent cryo-EM analysis revealed distinct differences in the folding patterns of heparin-induced recombinant tau filaments and AD tau filaments, this study focused on AD seed-dependent tau aggregation in drug repositioning for AD...
2024: Frontiers in Aging Neuroscience
https://read.qxmd.com/read/38629508/racial-and-ethnic-differences-in-plasma-biomarker-eligibility-for-a-preclinical-alzheimer-s-disease-trial
#3
JOURNAL ARTICLE
Doris Patricia Molina-Henry, Rema Raman, Andy Liu, Oliver Langford, Keith Johnson, Leona K Shum, Crystal M Glover, Shobha Dhadda, Michael Irizarry, Gustavo Jimenez-Maggiora, Joel B Braunstein, Kevin Yarasheski, Venky Venkatesh, Tim West, Philip B Verghese, Robert A Rissman, Paul Aisen, Joshua D Grill, Reisa A Sperling
INTRODUCTION: In trials of amyloid-lowering drugs for Alzheimer's disease (AD), differential eligibility may contribute to under-inclusion of racial and ethnic underrepresented groups. We examined plasma amyloid beta 42/40 and positron emission tomography (PET) amyloid eligibility for the ongoing AHEAD Study preclinical AD program (NCT04468659). METHODS: Univariate logistic regression models were used to examine group differences in plasma and PET amyloid screening eligibility...
April 17, 2024: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/38625863/generating-pet-scan-patterns-in-alzheimer-s-by-a-mathematical-model
#4
JOURNAL ARTICLE
Chaeyoung Lee, Avner Friedman
Alzheimer disease (AD) is the most common form of dementia. The cause of the disease is unknown, and it has no cure. Symptoms include cognitive decline, memory loss, and impairment of daily functioning. The pathological hallmarks of the disease are aggregation of plaques of amyloid-β (Aβ) and neurofibrillary tangles of tau proteins (τ), which can be detected in PET scans of the brain. The disease can remain asymptomatic for decades, while the densities of Aβ and τ continue to grow...
2024: PloS One
https://read.qxmd.com/read/38621736/visual-analysis-on-the-study-status-and-trends-of-acupuncture-and-moxibustion-for-alzheimer-s-disease
#5
JOURNAL ARTICLE
Le Cheng, Caifeng Zhu, Bingyuan Zhou, Jiayu Zhang, Chi Wang, Renfei Song, Li Tao
The research history, hot spots and frontier trends of acupuncture and moxibustion for Alzheimer's disease (AD) were explored using knowledge graph technology. The articles on acupuncture and moxibustion for AD were searched from 6 databases, i.e. CNKI, VIP, Wanfang, SinoMed, Pubmed and Web of Science, from January 1st, 1993 to January 1st, 2023. Using CiteSpace6.2.R2 Advance and VOSviewer V1.6.19 softwares, the knowledge map was graphed and the visual analysis was performed. A total of 1 228 Chinese and 309 English articles were included...
April 12, 2024: Zhongguo Zhen Jiu, Chinese Acupuncture & Moxibustion
https://read.qxmd.com/read/38618323/disease-modifying-treatments-and-their-future-in-alzheimer-s-disease-management
#6
REVIEW
Blake Smith, Raymond L Ownby
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by memory impairment, a loss of cholinergic neurons, and cognitive decline that insidiously progresses to dementia. The pathoetiology of AD is complex, as genetic predisposition, age, inflammation, oxidative stress, and dysregulated proteostasis all contribute to its development and progression. The histological hallmarks of AD are the formation and accumulation of amyloid-β plaques and interfibrillar tau tangles within the central nervous system...
March 2024: Curēus
https://read.qxmd.com/read/38610637/long-term-treatment-with-the-calcitonin-gene-related-peptide-receptor-antagonist-erenumab-in-cadasil-two-case-reports
#7
Maria Albanese, Francesca Pescini, Chiara Di Bonaventura, Luigi Francesco Iannone, Silvia Bianchi, Anna Poggesi, Mario Bengala, Nicola Biagio Mercuri, Francesco De Cesaris
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common monogenic form of cerebral small vessel disease, caused by a mutation in the NOTCH3 gene on chromosome 19. The main clinical features include migraine (often with aura), early onset, recurrent subcortical ischemic strokes, mood disturbances, and cognitive impairment, frequently leading to dementia and disability with a reduction in life expectancy. Cerebral chronic global hypoperfusion, due to impaired cerebrovascular reactivity, seems to play a primary role in CADASIL...
March 24, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38609945/assisted-dying-principles-possibilities-and-practicalities-an-english-physician-s-perspective
#8
REVIEW
Robert Twycross
It seems probable that some form of medically-assisted dying will become legal in England and Wales in the foreseeable future. Assisted dying Bills are at various stages of preparation in surrounding jurisdictions (Scotland, Republic of Ireland, Isle of Man, Jersey), and activists campaign unceasingly for a change in the law in England and Wales. There is generally uncritical supportive media coverage, and individual autonomy is seen as the unassailable trump card: 'my life, my death'.However, devising a law which is 'fit for purpose' is not an easy matter...
April 13, 2024: BMC Palliative Care
https://read.qxmd.com/read/38609734/association-of-tumor-necrosis-factor-%C3%AE-inhibitors-with-incident-dementia-analysis-based-on-population-based-cohort-studies
#9
JOURNAL ARTICLE
Saskia Berger, Kristine F Moseholm, Emilie R Hegelund, Falko Tesch, Minh Chau S Nguyen, Laust H Mortensen, Majken K Jensen, Jochen Schmitt, Kenneth J Mukamal
BACKGROUND AND OBJECTIVE: Preliminary evidence suggests a possible preventive effect of tumor necrosis factor-α inhibitors (TNFi) on incident dementia. The objective of the analysis was to investigate the association between TNFi and the risk of incident dementia in a population undergoing treatment for rheumatological disorders. METHODS: We followed patients aged ≥ 65 years with dementia and rheumatological conditions in two cohort studies, DANBIO (N = 21,538), a Danish clinical database, and AOK PLUS (N = 7112), a German health insurance database...
April 12, 2024: Drugs & Aging
https://read.qxmd.com/read/38607082/neuroprotection-of-cholinergic-neurons-with-a-tau-aggregation-inhibitor-and-rivastigmine-in-an-alzheimer-s-like-tauopathy-mouse-model
#10
JOURNAL ARTICLE
Maciej Zadrozny, Patrycja Drapich, Anna Gasiorowska-Bien, Wiktor Niewiadomski, Charles R Harrington, Claude M Wischik, Gernot Riedel, Grazyna Niewiadomska
Basal forebrain cholinergic dysfunction, most likely linked with tau protein aggregation, is a characteristic feature of Alzheimer's disease (AD). Recent evidence suggests that tau protein is a putative target for the treatment of dementia, and the tau aggregation inhibitor, hydromethylthionine mesylate (HMTM), has emerged as a potential disease-modifying treatment. However, its efficacy was diminished in patients already receiving approved acetylcholinesterase inhibitors. In this study, we ask whether this negative interaction can also be mimicked in experimental tau models of AD and whether the underlying mechanism can be understood...
April 6, 2024: Cells
https://read.qxmd.com/read/38603559/the-bis-monoacylglycero-phosphate-hypothesis-from-lysosomal-function-to-therapeutic-avenues
#11
REVIEW
Uche N Medoh, Monther Abu-Remaileh
Lysosomes catabolize and recycle lipids and other biological molecules to maintain cellular homeostasis in diverse nutrient environments. Lysosomal lipid catabolism relies on the stimulatory activity of bis(monoacylglycero)phosphate (BMP), an enigmatic lipid whose levels are altered across myriad lysosome-associated diseases. Here, we review the discovery of BMP over half a century ago and its structural properties that facilitate the activation of lipid hydrolases and recruitment of their coactivators. We further discuss the current, yet incomplete, understanding of BMP catabolism and anabolism...
April 11, 2024: Annual Review of Biochemistry
https://read.qxmd.com/read/38600444/potentially-inappropriate-prescribing-for-people-with-dementia-in-ambulatory-care-a-cross-sectional-observational-study
#12
JOURNAL ARTICLE
Nahla A Alageel, Carmel M Hughes, Monira Alwhaibi, Walid Alkeridy, Heather E Barry
BACKGROUND: Studies have shown that potentially inappropriate prescribing (PIP) is highly prevalent among people with dementia (PwD) and linked to negative outcomes, such as hospitalisation and mortality. However, there are limited data on prescribing appropriateness for PwD in Saudi Arabia. Therefore, we aimed to estimate the prevalence of PIP and investigate associations between PIP and other patient characteristics among PwD in an ambulatory care setting. METHODS: A cross-sectional, retrospective analysis was conducted at a tertiary hospital in Saudi Arabia...
April 10, 2024: BMC Geriatrics
https://read.qxmd.com/read/38597219/pharmacological-interventions-to-improve-sleep-in-people-with-alzheimer-s-disease-a-meta-analysis-of-randomized-controlled-trials
#13
REVIEW
Amy Bedward, Jasmine Kaur, Sadiyah Seedat, Holly Donohue, Chia Siang Kow, Muhammad Kamran Rasheed, Amaan Javed, Syed Shahzad Hasan
INTRODUCTION: This systematic review and meta-analysis evaluates the evidence from randomized controlled trials (RCTs) involving pharmacological interventions for improving sleep in people with Alzheimer's disease (AD). METHODS: A systematic literature search in eight databases from January 2000 to July 2023 focusing on RCTs that compared a pharmacological intervention with a placebo for enhancing sleep in people with AD. The authors registered the study protocol at Prospero, followed the PRISMA guidelines, and produced the pooled estimates using random-effect or IVhet models...
April 10, 2024: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38596484/clinical-value-of-alzheimer-s-disease-biomarker-testing
#14
JOURNAL ARTICLE
Khushbu J Patel, David Yang, John R Best, Colleen Chambers, Philip E Lee, Alexandre Henri-Bhargava, Clark R Funnell, Dean J Foti, Jacqueline A Pettersen, Howard H Feldman, Haakon B Nygaard, Ging-Yuek R Hsiung, Mari L DeMarco
INTRODUCTION: In the Investigating the Impact of Alzheimer's Disease Diagnostics in British Columbia (IMPACT-AD BC) study, we aimed to understand how Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarker testing-used in medical care-impacted medical decision-making (medical utility), personal decision-making (personal utility), and health system economics. METHODS: The study was designed as an observational, longitudinal cohort study. A total of 149 patients were enrolled between February 2019 and July 2021...
2024: Alzheimer's & Dementia: Translational Research & Clinical Interventions
https://read.qxmd.com/read/38595196/use-of-menopausal-hormone-therapy-beyond-age-65-years-and-its-effects-on-women-s-health-outcomes-by-types-routes-and-doses
#15
JOURNAL ARTICLE
Seo H Baik, Fitsum Baye, Clement J McDonald
OBJECTIVES: The study aims to assess the use of menopausal hormone therapy beyond age 65 years and its health implications by types of estrogen/progestogen, routes of administration, and dose strengths. METHODS: Using prescription drug and encounter records of 10 million senior Medicare women from 2007-2020 and Cox regression analyses adjusted for time-varying characteristics of the women, we examined the effects of different preparations of menopausal hormone therapy on all-cause mortality, five cancers, six cardiovascular diseases, and dementia...
April 9, 2024: Menopause: the Journal of the North American Menopause Society
https://read.qxmd.com/read/38586351/advancements-in-research-on-the-effects-of-panax-notoginseng-saponin-constituents-in-ameliorating-learning-and-memory-disorders
#16
REVIEW
Shusen Liu, Min Wang, Haiyan Xiao, Jingxue Ye, Li Cao, Wenlan Li, Guibo Sun
Learning and memory disorder is a cluster of symptoms caused by neuronal aging and other diseases of the central nervous system (CNS). Panax notoginseng saponins (PNS) are a series of saponins derived from the natural active ingredients of traditional Chinese medicine (TCM) that have neuroprotective effects on the central nervous system. In this paper, we review the ameliorative effects and mechanisms of Panax notoginseng saponin-like components on learning and memory disorders to provide valuable references and insights for the development of new drugs for the treatment of learning and memory disorders...
April 15, 2024: Heliyon
https://read.qxmd.com/read/38585870/ai-based-differential-diagnosis-of-dementia-etiologies-on-multimodal-data
#17
Chonghua Xue, Sahana S Kowshik, Diala Lteif, Shreyas Puducheri, Varuna H Jasodanand, Olivia T Zhou, Anika S Walia, Osman B Guney, J Diana Zhang, Serena T Pham, Artem Kaliaev, V Carlota Andreu-Arasa, Brigid C Dwyer, Chad W Farris, Honglin Hao, Sachin Kedar, Asim Z Mian, Daniel L Murman, Sarah A O'Shea, Aaron B Paul, Saurabh Rohatgi, Marie-Helene Saint-Hilaire, Emmett A Sartor, Bindu N Setty, Juan E Small, Arun Swaminathan, Olga Taraschenko, Jing Yuan, Yan Zhou, Shuhan Zhu, Cody Karjadi, Ting Fang Alvin Ang, Sarah A Bargal, Bryan A Plummer, Kathleen L Poston, Meysam Ahangaran, Rhoda Au, Vijaya B Kolachalama
Differential diagnosis of dementia remains a challenge in neurology due to symptom overlap across etiologies, yet it is crucial for formulating early, personalized management strategies. Here, we present an AI model that harnesses a broad array of data, including demographics, individual and family medical history, medication use, neuropsychological assessments, functional evaluations, and multimodal neuroimaging, to identify the etiologies contributing to dementia in individuals. The study, drawing on 51, 269 participants across 9 independent, geographically diverse datasets, facilitated the identification of 10 distinct dementia etiologies...
March 26, 2024: medRxiv
https://read.qxmd.com/read/38585197/formulation-and-characterization-of-polymeric-nanoparticle-of-rivastigmine-for-effective-management-of-alzheimer-s-disease
#18
JOURNAL ARTICLE
Faisal Imam, Sayantan Mukhopadhyay, Preeti Kothiyal, Samiyah Alshehri, Khalid Saad Alharbi, Muhammad Afzal, Muzaffar Iqbal, Mohammad Rashid Khan, Md Khalid Anwer, Abdulrazaq Ahmed Hattab Alanazi, Ali Ghanem Alqahtani, Mohammed Abdullah Alhamamah
Memory loss or dementia is a progressive disorder, and one of its common forms is Alzheimer's disease (AD), effecting mostly middle aged and older adults. In the present study, we developed Rivastigmine (RIV) nanoparticles using poly(lactic-co-glycolic acid) (RIV-loaded PLGA NPs) and polyvinyl alcohol (PVA). The prepared RIV-PLGA nanoparticles was evaluated for the management of Alzheimer's disease (AD). The nanoparticles were prepared by the slightly modified nano-precipitation technique. The developed formulations were evaluated for particle size, zeta potential (ZP), polydispersibility index (PDI) and surface morphology and drug content...
May 2024: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://read.qxmd.com/read/38583410/-traumatic-brain-injury-in-patients-over-65-years-of-age-attended-in-the-emergency-department-characteristics-and-complications
#19
JOURNAL ARTICLE
Josep Guil Sànchez
BACKGROUND AND OBJECTIVE: Ageing is associated with an increased risk of falls and trauma. The aim of the study was to assess the characteristics of patients over 65 years of age who consulted the ED for traumatic brain injury (TBI) in 2022, their relationship with cognitive impairment, functional dependence, use of oral antiplatelet/anticoagulant drugs and complications. MATERIALS AND METHODS: Retrospective study conducted from 1 January to 31 December 2022. Demographic data were collected: age, sex, origin; cardiovascular risk factors; cognitive impairment using the Pfeiffer questionnaire; physical disability according to the Barthel Index; number of drugs; use of antiplatelet and oral anticoagulant (OAC); mechanism of fall; performance of cranial X-ray/CT, and presence of complications: intracranial haemorrhage (ICH), death...
April 6, 2024: Revista Española de Geriatría y Gerontología
https://read.qxmd.com/read/38582410/the-role-of-the-cholinergic-system-in-the-memory-protecting-effects-of-metformin-in-a-model-of-scopolamine-induced-memory-impairment-in-aged-rats
#20
JOURNAL ARTICLE
Elif Aksoz, Busra Aslan Akyol, Oguzhan Korkut
PURPOSE: As the elderly population grows, the prevalence of dementia is also rapidly increasing worldwide. Metformin, an antidiabetic drug, has been shown to have ameliorative effects on impaired cognitive functions in experimental models. However, studies have generally used young animals. Additionally, although it has a major role in Alzheimer's disease (AD) and memory, literature information about the effects of metformin on the cholinergic system is limited. In this study, we investigated the effects of metformin on memory in a model of scopolamine-induced memory impairment in aged rats...
April 4, 2024: Behavioural Brain Research
keyword
keyword
64497
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.